Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. 2015

Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA. Electronic address: antgnelson@gmail.com.

The year 2016 will mark an important milestone - the 35th anniversary of the first reported cases of HIV/AIDS. Antiretroviral Therapy (ART) including Highly Active Antiretroviral Therapy (HAART) drug regimens is widely considered to be one of the greatest achievements in therapeutic drug research having transformed HIV infection into a chronically managed disease. Unfortunately, the lack of widespread preventive measures and the inability to eradicate HIV from infected cells highlight the significant challenges remaining today. Moving forward there are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new HIV infections from occurring, (2) to facilitate a functional cure, i.e., when HIV is present but the body controls it without drugs and (3) to eradicate established infection. Pre-exposure Prophylaxis (PrEP) represents a significant step forward in preventing the establishment of chronic HIV infection. However, the ultimate success of PrEP will depend on achieving sustained antiretroviral (ARV) tissue concentrations and will require strict patient adherence to the regimen. While first generation long acting/extended release (LA/ER) DD Systems (DDS) currently in development show considerable promise, significant DD treatment and prevention challenges persist. First, there is a critical need to improve cell specificity through targeting in order to selectively achieve efficacious drug concentrations in HIV reservoir sites to control/eradicate HIV as well as mitigate systemic side effects. In addition, approaches for reducing cellular efflux and metabolism of ARV drugs to prolong effective concentrations in target cells need to be developed. Finally, given the current understanding of HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and lymph nodes. The current review focuses on the DDS technologies, critical challenges, opportunities, strategies, and approaches by which novel delivery systems will help iterate towards prevention, functional cure and eventually the eradication of HIV infection.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D065129 Pre-Exposure Prophylaxis A method of disease prevention (abbreviated PrEP) which involves the administration of drugs to at-risk persons who have not been exposed to the disease-causing agent. Pre-Exposure Prophylaxis (PrEP),Pre Exposure Prophylaxis,Pre Exposure Prophylaxis (PrEP),Pre-Exposure Prophylaxi,Pre-Exposure Prophylaxi (PrEP),Prophylaxi, Pre-Exposure,Prophylaxi, Pre-Exposure (PrEP),Prophylaxis, Pre-Exposure,Prophylaxis, Pre-Exposure (PrEP)

Related Publications

Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
April 2019, Drugs,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
June 2020, AIDS patient care and STDs,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
February 2021, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
December 2020, Current HIV/AIDS reports,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
June 2013, Lancet (London, England),
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
December 2022, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
November 2017, Drug delivery,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
April 2012, Expert opinion on investigational drugs,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
January 2009, Journal of drug delivery science and technology,
Antoinette G Nelson, and Xiaoping Zhang, and Usha Ganapathi, and Zoltan Szekely, and Charles W Flexner, and Andrew Owen, and Patrick J Sinko
December 2012, International journal of preventive medicine,
Copied contents to your clipboard!